NASDAQ:MRTX Mirati Therapeutics (MRTX) Stock Price, News & Analysis → Move Your Money Before May 1 (From Stansberry Research) (Ad) Free MRTX Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$58.70▼$58.7050-Day Range$58.70▼$59.2852-Week Range$27.30▼$64.41VolumeN/AAverage Volume2.76 million shsMarket Capitalization$4.12 billionP/E RatioN/ADividend YieldN/APrice Target$60.00 Stock AnalysisStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsEarningsHeadlinesInsider TradesOwnershipShort InterestSocial MediaSustainability Get Mirati Therapeutics alerts: Email Address Mirati Therapeutics MarketRank™ Stock AnalysisAnalyst RatingHold2.21 Rating ScoreUpside/Downside2.2% Upside$60.00 Price TargetShort InterestN/ADividend StrengthN/ASustainability-0.68Upright™ Environmental ScoreNews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($11.39) to ($9.81) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.23 out of 5 starsMedical Sector892nd out of 908 stocksPharmaceutical Preparations Industry418th out of 424 stocks 1.1 Analyst's Opinion Consensus RatingMirati Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.21, and is based on 3 buy ratings, 11 hold ratings, and no sell ratings.Amount of Analyst CoverageMirati Therapeutics has received no research coverage in the past 90 days. Previous Next N/A Short Interest Short InterestThere is no current short interest data available for MRTX. Previous Next 0.0 Dividend Strength Dividend YieldMirati Therapeutics does not currently pay a dividend.Dividend GrowthMirati Therapeutics does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreMirati Therapeutics has received a 74.62% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is driven by its "Clinical research services for cancer", "Basic medical research services", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Mirati Therapeutics is -0.68. Previous Next 0.6 News and Social Media Coverage MarketBeat Follows1 people have added Mirati Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Mirati Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 3.26% of the stock of Mirati Therapeutics is held by insiders. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Mirati Therapeutics are expected to grow in the coming year, from ($11.39) to ($9.81) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mirati Therapeutics is -4.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mirati Therapeutics is -4.80, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMirati Therapeutics has a P/B Ratio of 3.39. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. About Mirati Therapeutics Stock (NASDAQ:MRTX)Mirati Therapeutics, Inc., a commercial-stage oncology company, develops novel therapeutics to address the genetic and immunological promoters of cancer in the United States. The company provides KRAZATI, an oral targeted treatment option for adult patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung (NSCLC), as well as in clinical development as a monotherapy and in combination with other agents. It also develops Sitravatinib, an investigational spectrum-selective kinase inhibitor in Phase 3 clinical development that inhibits receptor tyrosine kinases (RTKs), including TAM family receptors, split family receptors, and RET, which overcomes resistance to checkpoint inhibitor therapy through targeted reversal of an immunosuppressive tumor microenvironment that enhances antigen-specific T cell response and expanding dendritic cell-dependent antigen presentation. In addition, the company pipeline comprises the MRTX1719, an investigational synthetic lethal PRMT5 inhibitor designed to target the PRMT5/methylthioadensoine (MTA) complex and is in clinical development; MRTX0902, a selective SOS1 inhibitor that improves anti-tumor efficacy in combination with targeted mitogen-activated protein kinase (MAPK)-pathway inhibitors, and is in clinical development; and MRTX1133, an investigational lead KRAS G12D compound. It has a collaboration and license agreement with BeiGene, Ltd. to develop, manufacture, and commercialize sitravatinib; and Zai Lab Ltd. to research, develop, manufacture, and commercialize adagrasib in various indications. Mirati Therapeutics, Inc. was founded in 1995 and is headquartered in San Diego, California.Read More Ad Weiss RatingsThe Next Step of Their Control Is Here …Earlier this week, Section 702 of the Foreign Intelligence Surveillance Act (FISA) was renewed for an additional two years. What does this mean? It means the government has more time — and more ways — to surveil and control you.4 simple steps to protect your privacy and money before it’s too late. MRTX Stock News HeadlinesJanuary 10, 2024 | markets.businessinsider.comMirati Therapeutics Receives Marketing Authorization For KRAZATI From European CommissionJanuary 10, 2024 | finance.yahoo.comEuropean Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C MutationApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.December 25, 2023 | seekingalpha.comEvaluating Mirati Therapeutics' CVR Value In The Wake Of The Bristol Myers AcquisitionDecember 22, 2023 | reuters.comBristol Myers to buy schizophrenia drugmaker Karuna Therapeutics for $14 blnDecember 22, 2023 | msn.comKaruna Therapeutics soars after $14 billion takeover by Bristol MyersDecember 20, 2023 | msn.comCitigroup Downgrades Mirati Therapeutics (MRTX)December 20, 2023 | finance.yahoo.comMirati Therapeutics Inc EVP & Chief Scientific Officer Jamie Christensen Sells 2,387 SharesApril 26, 2024 | Weiss Ratings (Ad)Protect Yourself While There’s Still Time …The next step of the Fed's control is here. Section 702 of the Foreign Intelligence Surveillance Act was renewed for two more years and passed into law earlier this week. Allowing the Fed to tighten its grip on your personal privacy and freedom.December 15, 2023 | finance.yahoo.comInsider Sell Alert: EVP Benjamin Hickey Sells Shares of Mirati Therapeutics Inc (MRTX)December 12, 2023 | morningstar.comMirati Therapeutics Inc MRTXDecember 12, 2023 | finance.yahoo.comBillionaire Joe Lewis Keeps Trading Stocks Behind US Insider-Trading ChargesDecember 3, 2023 | benzinga.comMirati Therapeutics Stock (NASDAQ:MRTX), Short Interest ReportDecember 3, 2023 | benzinga.comMirati Therapeutics Stock (NASDAQ:MRTX) Dividends: History, Yield and DatesNovember 15, 2023 | benzinga.comMoore Kuehn Encourages PCTI, MRTX, CSTR, and BBAI Investors to Contact Law FirmNovember 10, 2023 | marketwatch.comMirati Therapeutics Gets CHMP Backing for KrazatiNovember 10, 2023 | reuters.comMirati's lung cancer drug gets EU's regulatory backingNovember 10, 2023 | finance.yahoo.comUPDATE 1-Mirati's lung cancer drug gets EU's regulatory backingNovember 8, 2023 | msn.comLeerink Partners Downgrades Mirati Therapeutics (MRTX)November 8, 2023 | msn.comStifel Downgrades Mirati Therapeutics (MRTX)November 7, 2023 | finance.yahoo.comParamount slashed 2 notches to sell; Ameresco in free fall: 5 big analyst cutsNovember 6, 2023 | finance.yahoo.comMirati Therapeutics Inc (MRTX) Reports Q3 2023 Financial ResultsNovember 6, 2023 | finance.yahoo.comMirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate UpdatesNovember 3, 2023 | marketwatch.comMirati Gets MHRA Approval for Krazati to Treat Non-Small Cell Lung Cancer PatientsNovember 2, 2023 | finance.yahoo.comKura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLCNovember 2, 2023 | msn.comMirati Therapeutics (MRTX) Price Target Increased by 16.97% to 64.71October 26, 2023 | finance.yahoo.comMirati Therapeutics Inc (26M.BE)See More Headlines Receive MRTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mirati Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/06/2023Today4/26/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MRTX CUSIPN/A CIK1576263 Webwww.mirati.com Phone(858) 332-3410FaxN/AEmployees587Year Founded2013Price Target and Rating Average Stock Price Target$60.00 High Stock Price Target$82.00 Low Stock Price Target$37.00 Potential Upside/Downside+2.2%Consensus RatingHold Rating Score (0-4)2.21 Research Coverage14 Analysts Profitability EPS (Most Recent Fiscal Year)($12.22) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-740,870,000.00 Net Margins-1,900.65% Pretax Margin-1,899.99% Return on Equity-82.15% Return on Assets-67.82% Debt Debt-to-Equity RatioN/A Current Ratio7.54 Quick Ratio7.40 Sales & Book Value Annual Sales$12.44 million Price / Sales331.01 Cash FlowN/A Price / Cash FlowN/A Book Value$17.31 per share Price / Book3.39Miscellaneous Outstanding Shares70,150,000Free Float67,861,000Market Cap$4.12 billion OptionableOptionable Beta0.77 Social Links Metaverse Stocks And Why You Can't Ignore ThemThinking about investing in Meta, Roblox, or Unity? Click the link to learn what streetwise investors need to know about the metaverse and public markets before making an investment.Get This Free Report Key ExecutivesDr. Charles M. Baum M.D. (Age 66)Ph.D., Founder, President, CEO & Director Comp: $1.07MDr. James G. Christensen Ph.D. (Age 56)Executive VP & Chief Scientific Officer Comp: $1.76MDr. Alan Bart Sandler M.D. (Age 67)Executive VP & Chief Medical Officer Comp: $591kMr. Aaron Ondrey (Age 48)Chief Financial Officer Ms. Betsy Gelfand CPAChief Accounting Officer, Principal Accounting Officer & VP of FinanceMr. John B. Moriarty Jr. (Age 56)J.D., Chief Legal Officer & Corporate Secretary Mr. Peter LeeChief Compliance OfficerMr. Michael E. Paolucci (Age 64)Chief People Officer Mr. Benjamin J. Hickey M.B.A. (Age 49)Chief Commercial Officer Comp: $769.03kDr. Kelly Covello Ph.D.VP & Head of Medical AffairsMore ExecutivesKey CompetitorsAlkermesNASDAQ:ALKSPerrigoNYSE:PRGOAlpine Immune SciencesNASDAQ:ALPNNuvalentNASDAQ:NUVLMadrigal PharmaceuticalsNASDAQ:MDGLView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Sold 392,939 shares on 3/11/2024Ownership: 7.565%Quarry LPSold 1,000 shares on 2/20/2024Ownership: 0.001%Madison Avenue Partners LPBought 417,427 shares on 2/16/2024Ownership: 0.595%Braslyn Ltd.Bought 3,135,966 shares on 2/15/2024Ownership: 4.470%Frazier Life Sciences Management L.P.Bought 80,000 shares on 2/15/2024Ownership: 0.114%View All Insider TransactionsView All Institutional Transactions MRTX Stock Analysis - Frequently Asked Questions Should I buy or sell Mirati Therapeutics stock right now? 14 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Mirati Therapeutics in the last twelve months. There are currently 11 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" MRTX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in MRTX, but not buy additional shares or sell existing shares. View MRTX analyst ratings or view top-rated stocks. What is Mirati Therapeutics' stock price target for 2024? 14 analysts have issued twelve-month price objectives for Mirati Therapeutics' stock. Their MRTX share price targets range from $37.00 to $82.00. On average, they expect the company's stock price to reach $60.00 in the next year. This suggests a possible upside of 2.2% from the stock's current price. View analysts price targets for MRTX or view top-rated stocks among Wall Street analysts. How were Mirati Therapeutics' earnings last quarter? Mirati Therapeutics, Inc. (NASDAQ:MRTX) announced its quarterly earnings results on Monday, November, 6th. The biotechnology company reported ($2.49) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($2.83) by $0.34. The biotechnology company earned $16.40 million during the quarter, compared to analysts' expectations of $18.80 million. Mirati Therapeutics had a negative net margin of 1,900.65% and a negative trailing twelve-month return on equity of 82.15%. Mirati Therapeutics's revenue was up 203.7% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($3.09) EPS. What other stocks do shareholders of Mirati Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Mirati Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), AbbVie (ABBV), QUALCOMM (QCOM), BioMarin Pharmaceutical (BMRN), Micron Technology (MU), Netflix (NFLX), Block (SQ), Alibaba Group (BABA) and DocuSign (DOCU). Does Mirati Therapeutics have any subsidiaries? The following companies are subsidiares of Mirati Therapeutics: MethylGene, MethylGene Inc., and Mirati Therapeutics B.V..Read More This page (NASDAQ:MRTX) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsThese AI trades triggered this morning (545% return)Prosper Trading AcademyExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingHe Is Giving Away BitcoinCrypto Swap ProfitsFed launches fourth dollar overhaulStansberry ResearchMan Who Predicted 2008: “This Will be Worse.”Altimetry Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mirati Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
